Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume 47, Issue 4, Pages 519-526
Publisher
SAGE Publications
Online
2013-04-03
DOI
10.1345/aph.1r614
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
- (2017) A. Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Ipilimumab in advanced melanoma
- (2012) Alberto Farolfi et al. MELANOMA RESEARCH
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
- (2012) Stephanie Andrews et al. Cancer Management and Research
- Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma
- (2011) Gregory K. Pennock et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
- (2011) Ahmad Tarhini et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
- (2011) Poulam M. Patel et al. EUROPEAN JOURNAL OF CANCER
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to RAF Inhibitors in Melanoma
- (2011) Andrew E. Aplin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma
- (2010) Amy Frankenthaler et al. MELANOMA RESEARCH
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy
- (2010) Keiran S.M. Smalley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Betting on immunotherapy for melanoma
- (2009) Mario Sznol Current Oncology Reports
- Next Generation of Immunotherapy for Melanoma
- (2008) John M. Kirkwood et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started